As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19. The antibody treatment now
is sotrovimab from GlaxoSmithKline and Vir Biotechnology, and it’s in short supply.
Read the rest of this story on qz.com. Become a member to get unlimited access to Quartz’s journalism.
Originally published on Quartz : Original article